Saint Mary’s Hospital set to deliver world-leading genomics project in fight against cancer and rare diseases
NHS England has today announced eleven centres across the
country that will lead the way in delivering the 100,000 Genomes
Project, one of which will be Saint Mary's Hospital,
The three-year project, launched by the Prime Minister earlier
this year, will transform diagnosis and treatment for patients with
cancer and rare diseases.
The initiative involves collecting and decoding 100,000 human
genomes - complete sets of people's genes - that will enable
scientists and doctors to understand more about specific
The project has the potential to transform the future of
healthcare. It could improve the prediction and prevention of
disease, enable new and more precise diagnostic tests, and
allow personalisation of drugs and other treatments to specific
Some participating patients will benefit because a conclusive
diagnosis can be reached for a rare and inherited disease more
quickly, or because a treatment for cancer can be targeted at the
particular genetic change that is present in the cancer. But for a
number of patients, the benefit will be in the improvement in our
knowledge of the influence of genetics on disease and how it is
expressed in an individual, how other people can be helped with
similar diseases in the future, and how different types of tests
can be developed to detect changes beyond the genome.
The 11 designated Genomic Medicine Centres (GMCs) in this wave 1
selection process are based across the country, covering areas
including Greater Manchester, Merseyside, Oxford, Birmingham and
the West Midlands, Southampton, Cambridge and the East of England,
Exeter and the South West Peninsula, and the North East. Over the
lifetime of the project NHS England's ambition is to secure over
100 participating NHS trusts. A further wave of GMCs will be
procured to ensure that there is comprehensive coverage across the
NHS in England.
The GMCs have a track-record of providing excellence in genomic
services and have been evaluated by NHS England to ensure they meet
the requirements to deliver the project.
It is anticipated that around 75,000 people will be involved,
which will include some patients with life threatening and
debilitating disease. Recruitment to the project will begin from
2nd February 2015.
After samples are collected, they will be sent securely to
Illumina who have been procured by Genomics England to sequence the
whole genome and to analyse it. Results will be sent back to the
NHS for validation and clinical action.
Professor Bill Newman, Professor of Translational
Genomic Medicine at The Manchester Centre for Genomic Medicine at
The University of Manchester and Honorary Consultant at Central
Manchester University Hospitals NHS Foundation Trust
"The doctors, genetic counsellors, nurses and scientists at the
Manchester Centre for Genomic Medicine at Saint Mary's Hospital and
colleagues at the Christie Hospital in Manchester are delighted to
have been selected to be a Genome Medicine Centre by the NHS. They
plan to work with colleagues at Salford Royal, Wythenshawe and
Pennine Trust Hospitals to use the new type of genetic testing
called whole genome sequencing to find out why some people have
certain types of rare health problems and to treat people with
cancer more effectively.
"The Saint Mary's team and Christie Hospital have already been
part of the successful pilot phase of this project and look forward
to working with their patients and their families to use this new
genetic testing to benefit as many as possible across the North
Professor Sir Bruce Keogh, NHS England's National
Medical Director, said: "This is an
achievable ambition which positions Britain to unlock longstanding
mysteries of disease on behalf of humankind. Embracing genomics
will position us at the forefront of science and make the NHS the
most scientifically advanced healthcare system in the world. This
is the start of a unique, exciting journey that will bring benefits
for patients, for the NHS and for society at large."
The first wave of 11 designated Genomic Medicine Centres
- East of England NHS GMC - designated for both cancer
and rare disease.
Led by Cambridge University Hospitals NHS Foundation Trust.
- South London NHS GMC - designated for both cancer and
Led by Guy's and St Thomas' NHS Foundation Trust.
- North West Coast NHS GMC - designated for both cancer
and rare disease.
Led by Liverpool Women's NHS Foundation Trust.
- Greater Manchester NHS GMC - designated for
both cancer and rare disease.
Led by Central Manchester University Hospitals NHS Foundation
- University College London Partners NHS GMC - designated
for both cancer and rare disease.
Led by Great Ormond Street Hospital NHS Foundation Trust.
- North East and North Cumbria NHS GMC - designated GMC
for rare disease only.
Led by The Newcastle upon Tyne Hospitals NHS Foundation
- Oxford NHS GMC - designated for both cancer and rare
Led by Oxford University Hospitals Foundation Trust.
- South West Peninsula NHS GMC - designated for both
cancer and rare disease.
Led by Royal Devon & Exeter NHS Foundation Trust.
- Wessex NHS GMC - designated for both cancer and rare
Led by University Hospital Southampton NHS Foundation Trust.
- Imperial College Health Partners NHS GMC - designated
for both cancer and rare disease.
Led by Imperial College Healthcare NHS Trust.
- West Midlands NHS GMC - designated for both cancer and
Led by University Hospitals Birmingham NHS Foundation Trust.